Show simple item record

dc.contributor.authorVilla, Shaun
dc.contributor.authorPillai, Manon
dc.contributor.authorGraham, Donna
dc.contributor.authorKilgour, Elaine
dc.contributor.authorOverton, Nicola LD
dc.contributor.authorVasudev, N
dc.contributor.authorHughes, A
dc.contributor.authorWalker, A
dc.contributor.authorDransfield, S
dc.contributor.authorThistlethwaite, Fiona C
dc.date.accessioned2019-03-29T14:22:29Z
dc.date.available2019-03-29T14:22:29Z
dc.date.issued2018en
dc.identifier.citationVilla S, Pillai M, Graham D, Kilgour E, Overton N, Vasudev N, et al. TRIBE; Tyrosine kinase inhibitor therapy in renal-cell carcinoma: Immune biomarker evaluation. Ann Oncol. 2018;29(suppl_6):20.en
dc.identifier.doi10.1093/anonc/mdy315.008en
dc.identifier.urihttp://hdl.handle.net/10541/621653
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1093/anonc/mdy315.008en
dc.titleTRIBE; tyrosine kinase inhibitor therapy in renal-cell carcinoma: immune biomarker evaluationen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentCancer Imaging Centre, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, Londonen
dc.identifier.journalAnnals of Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record